ストックスクリーナーアプリを入手
18.57
9.26%
1.575
アフターアワーズ：
18.48
-0.095
-0.51%
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics Confirms Key Decisions at Annual Meeting - TipRanks
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy - Yahoo Finance
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - The Globe and Mail
Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com
Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus
Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com Nigeria
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus
Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire
Breakthrough Sickle Cell Treatment BEAM-101 Secures FDA Orphan Drug Status After Strong Trial Results - Stock Titan
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India
FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus
Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan
Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New Treatment | BEAM Stock News - GuruFocus
BEAM Therapeutics’ SWOT analysis: base editing biotech stock shows promise amid challenges - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Deutsche Bank AG Has $1.67 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR - Endpoints News
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics To Present At RBC Capital Markets Global Conference; Webcast At 11:00 AM ET - Nasdaq
Mercer Global Advisors Inc. ADV Sells 4,568 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Tower Research Capital LLC TRC Sells 5,172 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics to Highlight New Data from BEAM-101 Program in - GuruFocus
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress | BEAM Stock News - GuruFocus
Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference - Nasdaq
Beam Therapeutics to Highlight New Data from BEAM-101 - GlobeNewswire
New Clinical Data Reveals: BEAM-101 Treatment Progress in 17 Sickle Cell PatientsKey Findings Coming - Stock Titan
News: The Latest Clinical Trial Updates from CRISPR Medicine News - CRISPR Medicine News
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp - Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Stifel Financial Corp - Defense World
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Beam Therapeutics (BEAM) Gains FDA RMAT Designation for BEAM-302 - GuruFocus
Beam : FDA Grants RMAT Designation To BEAM-302 For Alpha-1 Antitrypsin Deficiency Treatment - Nasdaq
FDA grants RMAT status to Beam’s AATD gene therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - Stock Titan
0.00%
2.33%
大文字化:
|
ボリューム (24 時間):